Consistently, the chemotactic response of CD19+ B cells to CXCL12 was also markedly increased in active SLE patients compared with those with inactive SLE and the controls (p = 0.004 and p = 0.001, respectively). Here, CXCL12 is linked to systemic lupus erythematosus.